Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical excipients industry, indicating a positive outlook compared to the broader market [4]. Core Insights - The pharmaceutical excipients industry is undergoing an upgrade, with increasing specialization and scale as the regulatory framework and standards improve. The industry is expected to mature gradually [6][30]. - The implementation of the 2025 edition of the Chinese Pharmacopoeia, effective from October 1, 2025, introduces 52 new standards for pharmaceutical excipients, a 15.5% increase from the 2020 edition, totaling 387 standards. This is anticipated to enhance product quality and competitiveness in international markets, facilitating import substitution [6][28]. - The report highlights the strong performance of leading companies in the sector, such as Shanhe Pharmaceutical Excipients, which is positioned well to support pharmaceutical companies amid international changes. The company has shown steady growth and impressive export performance [6][30]. Summary by Sections 1. Importance of Pharmaceutical Excipients - Pharmaceutical excipients are essential components in drug production, influencing drug efficacy and manufacturing processes. They account for approximately 70% of the entire drug formulation [14][23]. 2. Development of the Pharmaceutical Excipients Industry - The industry is experiencing high-quality development, driven by improved regulatory environments and growing domestic demand. The market is expected to expand significantly, with a focus on high-end excipients and new formulations [30][31]. - The report notes that the domestic pharmaceutical excipients market is projected to reach approximately 48.28 billion yuan in 2024, with solid dosage form excipients accounting for about 33.8 billion yuan [32]. 3. Key Companies to Watch - Shanhe Pharmaceutical Excipients is highlighted as a leading player in the solid dosage excipients sector, with a robust product matrix and core technological advantages [6][30]. - Shandong Heda, a key player in the plant capsule market, is also recommended for investment due to its growth potential driven by the expanding health supplement market [2][6]. 4. Market Trends and Projections - The global health supplement market is expected to grow at a CAGR of approximately 5.4% from 2023 to 2028, potentially reaching nearly 1.4 trillion USD by 2028. The Chinese health supplement market is projected to reach 423.7 billion yuan by 2027 [6][30]. - The plant capsule market is anticipated to grow significantly, with global revenues expected to rise from approximately 1.535 billion USD in 2024 to 2.568 billion USD by 2031, driven by demand in both health supplements and pharmaceutical applications [6][30].

Core Viewpoint - The article highlights the successful implementation of a research instrument sharing platform in Jiangsu, which has significantly reduced R&D costs and accelerated the domestic replacement of high-end pharmaceutical excipients [1][2]. Group 1: Instrument Sharing and Collaboration - Jiangsu Southeast Nano Materials Co., Ltd. faced challenges in developing synthetic phospholipid excipients due to a lack of high-end detection equipment and skilled personnel [1]. - The company utilized a shared service platform to collaborate with Jiangsu Food and Drug Vocational College, enabling access to advanced instruments and expertise, thus overcoming dual bottlenecks in detection and talent [1][2]. - The shared model has led to a win-win situation for both the company and the university, enhancing equipment utilization and aligning academic research with industry needs [2]. Group 2: Financial Impact and Policy Support - In 2024, the company received a total of 15,000 yuan in provincial and municipal technology innovation vouchers, effectively reducing R&D testing costs by 50% [2]. - The city has established a comprehensive policy support system, resulting in over 2,400 research instruments being shared, a threefold increase compared to 2024, benefiting more than 200 enterprises [3]. - A dual subsidy mechanism has been implemented, with a total of 2.034 million yuan allocated in subsidies by 2025, aimed at lowering innovation costs for enterprises [3]. Group 3: Future Directions - The city plans to continue promoting the inclusion of enterprise instruments in the network, focusing on key industries such as new pharmaceuticals to enhance full-chain services [3]. - The goal is to establish a benchmark for research instrument sharing in the northern Yangtze River Delta, stimulating innovation and supporting industrial transformation [3].

Group 1 - The stock price of Shanhe Pharmaceutical Excipients Co., Ltd. closed at 15.77 yuan on February 4, 2026, with an increase of 2.8% and a trading volume of 175,500 shares, amounting to a transaction value of 275 million yuan [1] - On February 4, the net inflow of main funds was 12.91 million yuan, while retail investors experienced a net outflow of 24.74 million yuan, indicating a mixed sentiment among different investor groups [2] - The company successfully passed its first on-site inspection by the U.S. FDA from December 4 to December 5, 2025, confirming that its quality management system meets international standards, which is expected to facilitate expansion into the U.S. and other international markets [1][2] Group 2 - The successful FDA inspection is anticipated to positively impact the company's ability to replace imported pharmaceutical excipients in the domestic market [1] - The company has received the Establishment Inspection Report (EIR) from the FDA, marking a significant milestone in its quality management recognition [1]

Core Viewpoint - The company, Anhui Shanhe Pharmaceutical Excipients Co., Ltd., successfully passed its first on-site inspection by the U.S. FDA, indicating that its quality management system meets international standards, which is expected to facilitate the expansion into U.S. and other international markets [1]. Group 1: Stock Performance - As of February 4, 2026, the stock price of Shanhe Pharmaceutical Excipients closed at 15.77 yuan, reflecting a 2.8% increase from the previous trading day [1]. - The stock opened at 15.35 yuan, reached a high of 16.01 yuan, and a low of 15.28 yuan, with a trading volume of 2.75 billion yuan and a turnover rate of 8.84% [1]. Group 2: FDA Inspection - The company underwent an on-site inspection by the U.S. FDA from December 4 to December 5, 2025, covering six major systems: quality management, production management, facility and equipment management, laboratory quality control, material and packaging label management [1]. - The company received the FDA's Establishment Inspection Report (EIR), confirming that the inspection was completed successfully [1]. Group 3: Market Implications - The successful FDA inspection is expected to positively impact the company's domestic pharmaceutical excipients business by reducing reliance on imports [1]. - The company cautions investors about potential risks to overseas business due to market conditions, tariffs, and exchange rates [1].

Core Viewpoint - Hualan Co., Ltd. has signed a share transfer agreement to acquire a 35% stake in Ningbo Guangfeng Capsule Co., Ltd. for 8.4647 million yuan, with plans to increase its ownership to between 51% and 70% by 2028 [1] Group 1: Company Acquisition - Hualan Co., Ltd. will purchase a 35% stake in Ningbo Guangfeng Capsule Co., Ltd. from Ningbo Spokan Biotechnology Co., Ltd. for 8.4647 million yuan [1] - After the transaction, Hualan will have the right to further acquire an additional 16% to 35% of Guangfeng Capsule's shares between 2026 and 2028 [1] - The acquisition aims to achieve controlling interest in Guangfeng Capsule, which specializes in the manufacturing and sales of hollow capsules, a pharmaceutical excipient [1]

Core Viewpoint - After 13 months of international trade disputes, Chinese hard capsule manufacturers have received a favorable ruling from the U.S. Department of Commerce, significantly reducing anti-dumping and countervailing duties, which enhances their competitiveness in the U.S. market [1][4]. Group 1: Impact of Ruling on Shandong Heda - Shandong Heda's anti-dumping tax rate has dropped from 172.24% to 18.71%, a reduction of 153.53 percentage points, while the countervailing duty is set at 6.90% [1][6]. - The substantial decrease in tax rates not only restores the company's export competitiveness but also allows for the refund of previously paid high-rate deposits, positively impacting cash flow [1][10]. - Following the announcement, Shandong Heda's stock price surged, indicating market optimism regarding the ruling's implications [1][10]. Group 2: Background of the Investigation - The investigation began on November 13, 2024, when the U.S. Department of Commerce initiated anti-dumping and countervailing duty investigations on hard capsules from China, Brazil, India, and Vietnam [4][5]. - At the initial ruling stage, Shandong Heda faced a punitive tax rate of 172.24%, which raised concerns about its market viability in the U.S. [5][6]. - The U.S. market is crucial for Shandong Heda, with exports to the U.S. accounting for 62.38% of its total revenue from hard capsules [3][4]. Group 3: Future Strategies - Despite the favorable ruling, uncertainties remain as the U.S. International Trade Commission will announce its final determination on industry damage in February 2026, which could affect the enforcement of the anti-dumping duties [3][11]. - Shandong Heda has prioritized establishing a manufacturing facility in the U.S. as a strategic move to mitigate tariff risks and enhance its market presence [3][11]. - The company is also expanding its global footprint beyond the U.S., targeting markets in Germany, France, Italy, Canada, Brazil, India, and Japan, and has signed an exclusive agency agreement with IMCD to penetrate emerging markets [12].

Core Points - The company reported a revenue of 697 million yuan for the first three quarters of 2025, representing a year-on-year growth of 8.09% [1] - The net profit attributable to shareholders for the same period was 133 million yuan, with a year-on-year increase of 8.28% [1] - In the third quarter alone, the company achieved a revenue of 226 million yuan, marking a year-on-year growth of 16.06% [1] - The net profit for the third quarter was approximately 39.53 million yuan, showing a significant year-on-year increase of 46.99% [1]

Core Viewpoint - The company Erkang Pharmaceutical (300267) showcases its strengths and development potential in the pharmaceutical excipients industry during the 2025 Hunan Listed Companies Collective Reception Day and Semi-Annual Performance Briefing held on September 19. Group 1: Company Strengths - The company offers a diverse range of products, with 127 pharmaceutical excipient varieties, accounting for 32.87% of the 387 varieties listed in the 2025 edition of the Chinese Pharmacopoeia, covering nearly all commonly used pharmaceutical excipients [1] - Established supply relationships with over 3,000 domestic downstream customers, indicating high product and customer stickiness [1] - Possesses three significant research platforms: the "National Pharmaceutical Excipients Engineering Technology Research Center," the "National Recognized Enterprise Technology Center," and the "Key Laboratory of Pharmaceutical Excipients Engineering Technology of the National Medical Products Administration" [1] - Actively participates in the formulation and revision of standards for pharmaceutical excipients in the Chinese Pharmacopoeia and contributes to the compilation of the "Infrared Spectrum Collection of Pharmaceutical Excipients" [1] - Awarded the qualification of "Variety Guardian" for 12 types of pharmaceutical excipients by the National Pharmacopoeia Committee [1] - Achievements in quality improvement research for injectable pharmaceutical excipients, with the project "Key Technology Development and Industrialization of Injectable Pharmaceutical Excipients" winning the second prize in Hunan Province's Science and Technology Progress Award [1] - The company's starch capsules and other varieties have been included in the list of key varieties in the biopharmaceutical industry chain published by the Hunan Provincial Department of Industry and Information Technology (second batch) [1]

Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd., is a significant event for the company, which may lead to changes in leadership but is not expected to disrupt its operations [1][3]. Group 1: Company Leadership - Yin Zhenglong passed away on August 26, 2025, at the age of 60, and had been the chairman and general manager since the company's inception [3][5]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. - The company announced that the board's functionality will remain intact, and the management team will continue its operations without interruption [3]. Group 2: Company Operations - Following Yin Zhenglong's death, the company will conduct a board election to fill the chairman position, with current director and general manager Song Daocai temporarily assuming the role [3][5]. - The company reported a revenue of 471 million yuan for the first half of 2025, a year-on-year increase of 4.65%, while the net profit attributable to shareholders was approximately 93 million yuan, a decrease of 2.61% [8]. - Basic earnings per share were reported at 0.40 yuan, down 2.44% year-on-year [8]. Group 3: Company Background - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, holding a leading position in the domestic market [8]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [8]. Group 4: Recent Developments - The company's official website has been changed to a black-and-white page, indicating a period of mourning [6]. - Yin Zhenglong had recently chaired a shareholders' meeting on August 18 and a board meeting on the morning of August 26, just hours before his passing [5].

Core Viewpoint - The chairman and actual controller of Shanhe Pharmaceutical Excipients, Yin Zhenglong, passed away at the age of 60, leading to a significant impact on the company's stock price and governance structure [1][3]. Company Overview - Shanhe Pharmaceutical Excipients is engaged in the research, production, and sales of pharmaceutical excipients, with main products including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms and injectable pharmaceutical excipients [2]. Impact of Chairman's Death - Following the announcement of the chairman's death, the company's stock price fell over 4%, closing at 13.64 yuan per share [3]. - The company’s official website has been changed to black and white as a sign of mourning [3]. - Yin Zhenglong was the founder and had served as chairman and general manager since the company's inception, playing a crucial role in its growth and listing on the Shenzhen Stock Exchange [3]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. Governance Transition - The company announced that it will promptly complete the election of a new chairman according to relevant laws and regulations [3]. - In the interim, the current director and general manager, Song Daocai, will assume the responsibilities of chairman and legal representative until a new chairman is elected [3].